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AdipocytesBerberine, a hypoglycemic agent, has been shown to decrease plasma free fatty acids (FFAs) level in insulin-
resistant rats. In the present study, we explored the mechanism responsible for the antilipolytic effect of
berberine in 3T3-L1 adipocytes. It was shown that berberine attenuated lipolysis induced by catecholamines,
cAMP-raising agents, and a hydrolyzable cAMP analog, but not by tumor necrosis factor α and a
nonhydrolyzable cAMP analog. Unlike insulin, the inhibitory effect of berberine on lipolysis in response to
isoproterenol was not abrogated bywortmannin, an inhibitor of phosphatidylinositol 3-kinase, but additive to
that of PD98059, an extracellular signal-regulated kinase kinase inhibitor. Prior exposure of adipocytes to
berberine decreased the intracellular cAMP production induced by isoproterenol, forskolin, and 3-isobutyl-1-
methylxanthine (IBMX), along with hormone-sensitive lipase (HSL) Ser-563 and Ser-660 dephosphorylation,
but had no effect on perilipin phosphorylation. Berberine stimulated HSL Ser-565 as well as adenosine
monophosphate-activated protein kinase (AMPK) phosphorylation. However, compound C, an AMPK
inhibitor, did not reverse the regulatory effect of berberine on HSL Ser-563, Ser-660, and Ser-565
phosphorylation, nor the antilipolytic effect of berberine. Knockdown of AMPK using RNA interference also
failed to restore berberine-suppressed lipolysis. cAMP-raising agents increased AMPK activity, which was not
additive to that of berberine. Stimulation of adipocytes with berberine increased phosphodiesterase (PDE) 3B
and PDE4 activity measured by hydrolysis of 3[H]cAMP. These results suggest that berberine exerts an
antilipolytic effect mainly by reducing the inhibition of PDE, leading to a decrease in cAMP and HSL
phosphorylation independent of AMPK pathway.nsitive lipase; PDE, phospho-
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Type 2 diabetes is characterized by insulin resistance and impaired
insulin secretion [1]. Elevated plasma levels of free fatty acids (FFAs) are
thought to play amajor role in thepathogenesis of insulin resistance and
type 2 diabetes by inhibiting glucose uptake and utilization by muscle
and causing increased glucose output by the liver [2–5]. In the pancreas,lipid accumulation in β cells may impair insulin secretion [6]. The
increases in plasma FFA levels are the result of increased mobilization
from adipose tissue. Hormone-sensitive lipase (HSL), thought to be the
rate-limiting enzyme in adipose tissue lipolysis, hydrolyzes the stored
triglycerides into monoglycerides and FFA [7].
Cyclic AMP is an important second messenger in the signaling
pathways that mobilize fat stores [8]. Catecholamines stimulate
adipocyte lipolysis by binding to β-adrenoceptors, which activate
adenylyl cyclase via the stimulatory guanine nucleotide binding protein
(Gs), leading to an increase in intracellular cAMP and activation of
cAMP-dependent protein kinase A (PKA). PKA then phosphorylates
both perilipins and HSL. The phosphorylation of HSL is associated with
an increase in hydrolytic activity of the enzyme and the translocation of
HSL from the cytosol to the lipid droplet [9]. In contrast, insulin acutely
inhibits lipolysis via inhibition of the above cAMP-dependent pathway
by PKB-dependent phosphorylation and activation of phosphodiester-
ase 3B (PDE3B), which in turn lowers cAMP levels [10].
Berberine, one of the major constituents of Chinese herb Rhizoma
coptidis, is an isoquinoline alkaloid. Clinical trials and animal experi-
ments reported that berberine improved insulin resistance and lowered
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AMP-activated protein kinase (AMPK) contributing to its beneﬁcial
metabolic effects in peripheral tissues [13,14]. In addition, berberine has
been described as a new cholesterol-lowering drug [15]. We found that
berberine decreased plasma FFA level in high fat diet-induced insulin-
resistant rats [16] as reported previously in diabetic rats [17]. However,
the cellular mechanism underlying berberine decreasing plasma FFA
level has not yet been elucidated.
In the present study, we characterized the effect of berberine on
lipolysis induced by various agonists in 3T3-L1 adipocytes and
investigated whether cAMP signaling pathway was involved in the
antilipolytic actionof berberine. Treatmentof adipocyteswith berberine
attenuated lipolysis stimulated by catecholamines and cAMP-raising
agents, not by tumor necrosis factor α (TNF-α) and a nonhydrolyzable
cAMP analog, which was mainly attributed to the activation of PDE,
leading to the reduction of cAMP production and inhibition of HSL
activation.
2. Materials and methods
2.1. Materials
Dulbecco's modiﬁed Eagle's medium (DMEM) and other culture
reagentswere obtained fromGibco Life Technologies (Grand Island, NY).
The cell culture plates were purchased from Nalge Nunc International
(Roskilde, Denmark). Human insulin (Humulin R) was from Eli Lilly S.A.
S. (Fegersheim, France). 8-Bromo-cAMP, dibutyryl cAMP, cAMP,
forskolin, isoproterenol, noradrenaline, 3-isobutyl-1-methylxanthine
(IBMX), 5-aminoimidazole-4-carboxamide riboside (AICAR), PD98059,
wortmannin, H89, TNF-α, cilostamide, rolipram, fatty acid-free bovine
serum albumin (BSA), anti-perilipin A, GPO-Trinder glycerol assay
reagent, N-TER™ Nanoparticle siRNA transfection reagent, and direct
cAMP enzyme immunoassay kit were purchased from Sigma (St Louis,
MO, USA). anti-extracellular signal-regulated kinase 1/2 (ERK 1/2), anti-
phospho-ERK1/2, anti-AMPK, anti-phospho-AMPK (Thr172), anti-ace-
tyl-coenzyme A carboxylase (ACC), anti-phospho-Ser-79 ACC, anti-HSL,
anti-phospho-HSL (Ser-563), anti-phospho-HSL (Ser-565), anti-phos-
pho-HSL (Ser-660), anti-rabbit IgG conjugated with horseradish
peroxidase were from Cell Signaling Technology (Beverly, MA, USA).
Compound C was purchased from Calbiochem (San Diego, CA). [3H]
cAMP was from PerkinElmer Life Sciences (Boston, MA, USA). Murine-
derived 3T3-L1 ﬁbroblasts were purchased from American Type Culture
Collection (Rockville, MD). Berberine was obtained from the National
Institute for the Control of Pharmaceutical and Biological Products
(Beijing, China).
2.2. Cell culture and differentiation
3T3-L1 preadipocytes were grown and passaged in DMEM contain-
ing 25 mM glucose plus 10% fetal bovine serum (FBS). For adipocyte
differentiation, 2-daypostconﬂuent cellswere placed in10% FBS-DMEM
with 250 nM dexamethasone, 0.5 mM IBMX, and 1 μg/ml insulin. After
2 days, themediumwas changed to 10% FBS-DMEM containing 1 μg/ml
insulin alone for 2 additional days and was replaced with 10% FBS-
DMEM. Thereafter, the medium was changed every 2 days [18]. Cells
were used between days 8 and 10 postdifferentiation and between
passages 6 and 12.
2.3. Measurement of glycerol release
The differentiated 3T3-L1 adipocytes in 96-well plates were
preincubated with serum-free DMEM containing 0.2% BSA for 12 h
before lipolysis experiments. Cells were subjected to the treatments
described in each ﬁgure legend in phenol red-free DMEM containing
2% fatty acid-free BSA. Glycerol content in the incubationmediumwas
used as an index for lipolysis and was measured using a colorimetricassay (GPO-Trinder, Sigma, St. Louis, MO, USA). Brieﬂy, supernatant
was mixed with GPO-Trinder reagent A, and optical density was
measured at 540 nm [19].
2.4. cAMP measurement
To measure cAMP levels, the differentiated 3T3-L1 adipocytes in
24-cell plates were incubated in serum-free DMEM containing 0.2%
BSA for 12 h and subjected to 10 μM berberine for 1 h followed by
1 μM isoproterenol, 10 μM forskolin, or 0.5 mM IBMX stimulation for
another 1 h. The cells were immediately lysed, and the cellular cAMP
levels were measured using an enzyme immunoassay kit (Sigma, St
Louis, MO, USA).
2.5. Assay of PDE activity
PDEactivitywasmeasured as described previously [20]: 100 μl assay
volume contained 50 mmol/l Tris–HCl buffer, pH 7.8, 10 mmol/l MgCl2,
2 μmol/l cAMP, and [3H]cAMP (40,000 cpm/assay). Reactions were
started by addition of 25 μl cell lysate and incubated at 24 °C for 30 min
and stopped by addition of 0.2 ml of 0.2 mol/l ZnSO4 and 0.2 ml of
0.2 mol/l Ba(OH)2. The samples were vortexed and centrifuged at
10,000×g for 3 min. The labeled product of the reaction 3H-5′ AMPwas
precipitated with BaSO4, and the unreacted 3H-cAMP remained in the
supernatant. Radioactivity in the supernatant was determined by liquid
scintillation counter. The PDE activity was determined as the amount of
cAMP hydrolyzed during the reaction time.
2.6. Western blotting
Cells in six-well plates were washed twice with ice-cold PBS and
placed immediately in lysis buffer containing25 mMHEPES (pH7.4), 1%
Nonidet P-40, 100 mMNaCl, 2% glycerol, 5 mMNaF, 1 mMEDTA, 1 mM
Na3VO4, 1 mM NaPPi, 1 mM phenylmethylsulfonyl ﬂuoride (PMSF),
10 μg/ml aprotinin, 5 μg/ml leupeptin, and 5 μg/ml pepstatin. Lysates
were gently mixed for 10 min at 4 °C and then centrifuged at 13,000×g
for 15 min at 4 °C. The protein concentration of the extracts was
determined according to the method of Bradford, using BSA as the
standard. Protein samples were separated by 10% SDS-PAGE and
transferred to nitrocellulose membranes. The transferred membranes
were blocked, washed, and incubated with various primary antibodies,
followed by horseradish peroxidase-conjugated secondary antibody.
Visualization was detected with chemiluminescence reagent, using the
ECL Western blotting analysis system (Amersham Biosciences).
2.7. Knockdown of AMPKα by RNA interference
To reduce levels of endogenous AMPKα, 3T3-L1 adipocytes were
transfected with a pool of three siRNAs for AMPKα (sc-45313; Santa
Cruz Biotechnology) using N-TER™ Nanoparticle siRNA transfection
reagent and incubated for 72 h. The speciﬁc interference of AMPK
protein expression was conﬁrmed by Western blot.
2.8. Statistics
Data are presented as means±SEM. Signiﬁcance between groups
was determined using an unpaired two-tailed Student's t-test or one-
way ANOVA when appropriate. Signiﬁcance was established at Pb0.05.
3. Results
3.1. Berberine attenuated lipolysis stimulated by catecholamines, but not
by TNF-α
Fully differentiated 3T3-L1 adipocytes were preincubated with
various concentrations of berberine for 1 h followed by the incubation
Fig. 1. Effect of berberine on catecholamines-stimulated lipolysis in 3T3-L1 adipocytes.
3T3-L1 adipocytes were incubated with the indicated concentrations of berberine
(BBR) for indicated time and then were stimulated with 1 μM isoproterenol (ISO) or
1 μM noradrenaline (NA) for further 1 h. The medium was removed for glycerol
measurement. (A) 3T3-L1 adipocytes were incubated with various concentrations of
BBR for 1 h. (B) 3T3-L1 adipocytes were incubated with 10 μM BBR for various time.
(C) 3T3-L1 adipocytes were incubated with 10 μM BBR for 1 h. Data are expressed as
mean±SEM (n=9). *Pb0.05, **Pb0.01 vs. isoproterenol or noradrenaline alone.
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determined as a measure of the rate of lipolysis. As shown in Fig. 1A,
berberine decreased lipolysis induced by isoproterenol in 3T3-L1
adipocytes with the maximal effect at the concentration of 10 μM. A
time course study depicted in Fig. 1B showed that berberine exerted a
similar magnitude of antilipolytic effect with 31–39% decrease in
glycerol release after 1-, 6-, and 24-h preincubation. 3T3-L1 adipocytes
incubated with 1 μM noradrenaline for 1 h showed a 616% increase in
glycerol release, which was suppressed 48% by 10 μM berberine
(Fig. 1C). In the basal state, treatment with 1–100 μM berberine for
24 h did not affect glycerol release signiﬁcantly (data not shown). To
determine whether berberine also exerts an antilipolytic effect on TNF-
α-stimulated lipolysis, 3T3-L1 adipocytes were incubated in the
presence of 10 ng/ml TNF-α in combination with 10 μM berberine.
After treatment with TNF-α for 6, 12, and 24 h, glycerol release
increased by 88%, 121%, and 70%, respectively. However, berberine had
no effect on lipolysis in response to TNF-α (data not shown).
3.2. Berberine attenuated lipolysis stimulated by forskolin, IBMX, and
cAMP
Catecholamines stimulate lipolysis through increasing intracellular
cAMPandactivatingHSL [9]. Todeterminewhetherberberine exerts the
same effect on other cAMP-raising agents-stimulated lipolysis, 3T3-L1
adipocytes were preincubated with 10 μM berberine for 1 h and then
stimulated by 10 μM forskolin, an activator of adenylyl cyclase, and
0.5 mM IBMX, a nonselective PDE inhibitor, for another 1 h. The results
showed that forskolin- and IBMX-stimulated lipolysis were decreased
by46% and 29%, respectively (Pb0.01). Furthermore, pretreatmentwith
berberine also resulted in a 56% decrease in lipolysis induced by 8-
bromo-cAMP, a hydrolyzable cAMP analog (Pb0.01, Fig. 2A). However,
berberine did not decrease dibutyryl cAMP, a nonhydrolyzable cAMP
analog-stimulated lipolysis,whichwas inhibited byH89, a PKA inhibitor
(Pb0.01, Fig. 2B).
3.3. Effect of various kinases inhibitors on berberine-inhibited lipolysis
It has been shown that components regulating adipocyte lipolysis
are cytoplasmic targets of mitogen-activated protein kinase (MAPK)
and that a portion of β-adrenergic-stimulated lipolysis in 3T3-L1
adipocytes is mediated via ERK [21]. As expected, PD98059, an ERK
kinase inhibitor, inhibited ERK phosphorylation (Fig. 3A). Fig. 3B
showed that PD98059 and berberine decreased lipolysis by 54% and
30%, respectively. Combined treatment with PD98059 and berberine
completely abolished isoproterenol-stimulated lipolysis, suggesting
that both agents act synergistically via different mechanisms. The
lipolysis in response to isoproterenol combined with IBMX was
markedly suppressed by berberine plus PD98059, not by berberine
alone (Fig. 3B). Many studies indicate that insulin activates phosphoi-
nositide 3-kinase (PI3K). Wortmannin, a selective and potent inhibitor
of this enzyme, antagonizes all of the metabolic effects of the hormone,
including inhibition of lipolysis in rat adipocytes [22]. Our previous
studies showed that berberine stimulated glucose uptake independent
of PI3K signalingpathway [23]. To further investigatewhether berberine
inhibits lipolysis via a mechanism distinct from insulin, we examined
the effect of wortmannin on berberine-inhibited lipolysis. As reported
previously [24], 1 μM wortmannin signiﬁcantly reversed the antilipo-
lytic effect of insulin in thepresence of isoproterenol but hadnoeffect on
berberine-inhibited lipolysis (Fig. 3C).
Recent study showed that AMPKactivation inhibited lipolysis [25]. It
has been shown that berberine stimulated AMPK activity in 3T3-L1
adipocytes, as well as in other cells [14,16,26]. To clarify whether AMPK
activation is involved in berberine-inhibited lipolysis, 10, 20, and 50 μM
compoundC, anAMPK inhibitor,waspreincubated30 minbefore 10 μM
berberine was added. As shown in Fig. 3D and E, compound C did not
reverse berberine-inhibited lipolysis in response to isoproterenol.
Fig. 2. Effect of berberine on lipolysis induced by cAMP-raising agents and cAMP.
(A) 3T3-L1 adipocytes were incubated with 10 μM berberine (BBR) for 1 h and then
stimulated with 10 μM forskolin (FKL), 0.5 mM 3-isobutyl-1-methylxanthine (IBMX),
and 1 mM 8-bromo-cAMP for another 1 h. (B) 3T3-L1 adipocytes were incubated with
10 μM BBR and 10 μMH89 for 1 h and then stimulated with 0.5 mM dibutyryl cAMP for
another 1 h. The medium was removed for glycerol measurement. Data are expressed
as mean±SEM for three experiments. *Pb0.01 vs. CON (without berberine), #Pb0.01
vs. dibutylryl cAMP alone.
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To test whether berberine mediates its antilipolytic effect via
lowering cAMP production, we detected intracellular cAMP levels.
After preincubation with 10 μM berberine for 1 h, 3T3-L1 adipocytes
were stimulated with 1 μM isoproterenol, 10 μM forskolin, and
0.5 mM IBMX for another 1 h. The results showed that no signiﬁcant
change in intracellular cAMPwas detected after stimulation of 3T3-L1
adipocytes with berberine in the basal state. Isoproterenol, forskolin,
and IBMX treatment strongly elevated cAMP levels. Berberine
markedly decreased isoproterenol-, forskolin-, and IBMX-potentiated
cAMP production by 39%, 43%, and 23%, respectively (Fig. 4A).3.5. Effect of berberine on PDE activity
As the aforementioned results suggested that berberine decreased
lipolysis via hydrolyzing cAMP, we further detected whether
berberine increased PDE activity. In basal state, PDE activity was not
changed by berberine; however, berberine increased IBMX, cilosta-
mide, and rolipram-inhibited PDE activity by 48%, 26%, and 41%,
respectively (Fig. 4B).3.6. Effect of berberine on HSL and AMPK phosphorylation
The activity of HSL is regulated by both phosphorylation and
translocation to the lipid droplet. PKA phosphorylates HSL at Ser-563,
Ser-659, and Ser-660 [27]. AMPK activation stimulates the phosphor-
ylation of HSL at Ser-565 [28]. We detected the HSL phosphorylation
at Ser-563, Ser-660, and Ser-565. Berberine at the concentrations of
0.1–100 μM completely inhibited HSL Ser-563 phosphorylation
mediated by isoproterenol. However, HSL Ser-660 phosphorylation
was completely inhibited by berberine only at the concentration of
10 μMor higher (Fig. 5A). Consistent with this result, 10 μMberberine
also dramatically inhibited HSL Ser-563 and Ser-660 phosphorylation
induced by noradrenaline, forskolin, and IBMX, as well as by 8-bromo-
cAMP (Fig. 5B and C). Unlike Ser-563 and Ser-660, HSL Ser-565 was
phosphorylated to a high degree already in non-stimulated adipo-
cytes. Berberine further enhanced HSL Ser-565 phosphorylation
(Fig. 5B).
To evaluate the role of AMPK in the regulation of berberine on
lipolysis, we used compound C to detect the effect of berberine on
HSL phoshporylation. Compound C did not reverse the regulation of
berberine on HSL Ser-563, Ser-660, and Ser-565 phosphorylation in
the presence of isoproterenol (Fig. 5D). We then detected the
phosphorylation state and activity of the enzyme after exposure of
3T3-L1 adipocytes to berberine for various time points. The
increased phosphorylation of AMPK and ACC was detectable
15 min after the addition of berberine and reached the maximum
at 30 min (Fig. 6A). Compound C inhibited AICAR-stimulated the
phosphorylations of ACC and AMPK, not berberine-stimulated ACC
and AMPK phosphorylations (Fig. 6B and C). We further transfected
AMPKα siRNA into 3T3-L1 adipocytes using N-TER™ Nanoparticle
siRNA transfection reagent. AMPKα protein expression was knocked
down at least 50% (Fig. 6D). However, berberine-suppressed
lipolysis was not reversed (Fig. 6E). After 3T3-L1 adipocytes were
incubated with forskolin and IBMX for 1 h, AMPK was also activated,
but two agents and berberine had no additive effect on AMPK
phosphorylation (Fig. 6F).
3.7. Effect of berberine on perilipin and ERK1/2 phosphorylation
Perilipin, like HSL, is described to be phosphorylated in response to
PKA activation and is involved in the lipolytic reaction of fat cells. To
examine whether the antilipolytic effect of berberine is related to
phosphorylation of perilipin in differentiated 3T3-L1 adipocytes, we
detected perilipin electrophoretic shift after adipocytes were incu-
bated with isoproterenol, forskolin, and berberine. As depicted in
Fig. 7, isoproterenol and forskolin induced the characteristic shift in
the migration of perilipin, whereas such electrophoretic shift was not
changed by berberine. However, PD98059 inhibited isoproterenol-
stimulated perilipin and ERK1/2 phosphorylation. Interestingly,
berberine also suppressed ERK1/2 phosphorylation induced by
isoproterenol and forskolin.
4. Discussion
Obesity and type 2 diabetes mellitus are associated with increased
levels of circulating FFA, which are thought to induce insulin resistance
[29].We found that berberine treatment signiﬁcantly decreased plasma
FFA in insulin-resistant rats induced by high-fat diet feeding for
20 weeks [16], which, at least in part, contributes to the mechanism
underlying berberine increasing insulin sensitivity. The present study
showed that berberine directly decreased catecholamines-stimulated
lipolysis in 3T3-L1 adipocytes, not basal and TNF-α-stimulated lipolysis.
As shown in Fig. 1A, berberine exerted themaximal effect on lipolysis at
the concentration of 10 μM, in consistent with its effect on glucose
uptake in 3T3-L1 adipocytes [23]. However, the time course study
showed that the antilipolytic effect of berberine did not increase with
Fig. 3. Effects of various kinases inhibitors on the antilipolytic effect of berberine. (A) 3T3-L1 adipocytes were preincubated with 50 μM PD98059 for 30 min followed by incubation
with 1 μM isoproterenol for 1 h. The cell lysates were analyzed by Western blot for the phosphorylation of ERK. (B) 3T3-L1 adipocytes were incubated in the presence of 50 μM
PD98059, 10 μM berberine (BBR) or PD98059 plus BBR for 1 h, and then stimulated with 1 μM isoproterenol or 0.5 mM IBMX for another 1 h. (C) After 3T3-L1 adipocytes were
incubated with 1 μM wortmannin for 30 min, 10 μM BBR or 10 nM insulin was added and incubation was continued for 1 h. 3T3-L1 adipocytes were stimulated with 1 μM
isoproterenol for another 1 h. (D, E) 3T3-L1 adipocytes were preincubated with 10, 20, or 50 μM compound C for 30 min followed by incubation with 10 μM BBR for 1 h. 3T3-L1
adipocytes were stimulated with 1 μM isoproterenol for another 1 h. The mediumwas removed for glycerol measurement. Data are expressed as mean±SEM for three experiments.
*Pb0.01 vs. isoproterenol alone.
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glucose uptake [23], suggesting that there exist different mechanisms
for the effects of berberine on lipolysis and glucose uptake.There is much to suggest that catecholamines activate not only
PKA but also ERK 1/2. PKA and ERK1/2 work in concert to stimulate
lipolysis [20]. As shown in Fig. 4A, isoproterenol-stimulated lipolysis
Fig. 4. Effect of berberine on cAMP levels and PDE activity in 3T3-L1 adipocyte. (A) 3T3-L1
adipocytes were preincubated with 10 μM berberine (BBR) for 1 h, and then stimulated
with 1 μM isoproterenol (ISO), 10 μM forskolin (FKL), and 0.5 mM IBMX for another 1 h.
The cellswereextracted for cAMPassay. (B) 3T3-L1 adipocyteswere incubatedwith10 μM
BBR for 30 min, and then incubated with 0.5 mM 3-isobutyl-1-methylxanthine (IBMX),
10 μM cilostamide (CIL), and 50 μM rolipram (ROL) for another 30 min. PDE activity was
assayed as described in experiment methods. The results are expressed as mean±SEM
(n=8–10) of three separate experiments. **Pb0.01, *Pb0.05 vs. CON (without berberine).
Fig. 5. Effect of berberine on HSL phosphorylation induced by various agonists. 3T3-L1
adipocytes were incubated with the indicated concentrations of berberine (BBR) for
1 h, and then stimulated with 1 μM isoproterenol (ISO), 0.5 mM IBMX, 1 μM
noradrenaline (NA), 10 μM forskolin (FKL), and 1 mM bromo-cAMP for another 1 h.
(A) ISO. (B) IBMX and NE. (C) FKL and 8-bromo-cAMP. (D) After 3T3-L1 adipocytes
were incubated in the presence of 10 μM compound C for 30 min, and 10 μM BBR was
added for 1 h. The cells were stimulated with 1 μM isoproterenol for another 1 h. The
cell lysates were analyzed by Western blot for the phosphorylation of HSL on Ser-563,
Ser-660, and Ser-565. The ﬁgure shown is 1 of 3 independent experiments. All 3
experiments showed similar results.
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abrogated by combined treatment with berberine and PD98059,
suggesting that cAMP-PKA signaling pathway is involved in the
inhibitory effect of berberine on lipolysis induced by catecholamines.
The ability of insulin to antagonize hormone-induced lipolysis is to a
large extent accounted for by its ability to lower cAMP levels and
therefore PKA activity. The decrease in cAMP is mainly the result of an
insulin activation of PDE3B via PKB signaling [30]. As shown in Fig. 3B,
wortmannin, a PI3K inhibitor, abrogated insulin-mediated antilipoly-
tic effect. However, wortmannin had no effect on berberine-inhibited
lipolysis, in agreement with the results of our previous study that
berberine stimulated glucose uptake independent of PI3K pathway
[23].
Catecholamines stimulated lipolysis primarily via cAMP-mediated
activation of PKA. In addition to catecholamines, lipolysis was alsostimulated by a variety of agonists such as forskolin (an activator of
adenylyl cyclase), IBMX (a nonselective PDE inhibitor), and 8-bromo-
cAMP (a hydrolyzable cAMP analog), which function at different
levels of the lipolytic cascade [31,32]. The present study showed that
berberine attenuated the three agonists-stimulated lipolysis but had
no effect on dibutyryl cAMP (a nonhydrolyzable cAMP analog)-
stimulated lipolysis. Furthermore, it was conﬁrmed that berberine
decreased the intracellular cAMP production induced by isoprotere-
nol, forskolin, and IBMX. These results suggest that berberine may
exert its antilipolytic effect via a step before PKA, activation of PDE. As
Fig. 6. Knockdown of AMPKα did not reverse berberine-suppressed lipolysis. (A) 3T3-L1 adipocytes were incubated with 10 μM berberine (BBR) for the indicated time. The
phosphorylation of ACC (Ser-79) and AMPK (Thr172) was detected by Western blot. (B, C) 3T3-L1 adipocytes were preincubated with 10, 20, or 50 μM compound C for 30 min
followed by incubation with 10 μM BBR and 1 mM AICAR for 1 h. The phosphorylation of ACC (Ser-79) and AMPK (Thr172) was detected by Western blot. (D) 3T3-L1 adipocytes
were transfected with AMPKα or control scrambled siRNAs (60 nM) for 72 h. Total AMPKα protein expression was determined by Western blot. (E) 72 h post-transfection, 3T3-L1
adipocytes were preincubated with 10 μM berberine for 1 h, and stimulated with 1 μM isoproterenol (ISO) for another 1 h. The medium was removed for glycerol measurement.
(F) 3T3-L1 adipocytes were incubated with 10 μM BBR, 10 μM forskolin (FKL), and 0.5 mM 3-isobutyl-1-methylxanthine (IBMX) for 1 h. The cell lysates were analyzed by Western
blot for the phosphorylation of ACC and AMPK. The ﬁgure shown is 1of 3 independent experiments. All 3 experiments showed similar results.
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cilostamide (a PDE3B inhibitor), or rolipram (a PDE4 inhibitor).
Acute activation of HSL has been shown to be controlled by
phosphorylation/dephosphorylation events, which are regulated by
the respective activities of cAMP-dependent PKA and protein phospha-
tase [33]. The enzyme is subject to complex activity regulation involving
multisite phosphorylation. For a long time, Ser-563 was believed to be
the only PKA site of HSL, which confers activity control. Using site-
directed mutagenesis, it was possible to elucidate that sites Ser-659 andSer-660 are critical activity-controlling sites in the activation ofHSLupon
phosphorylation with PKA, whereas Ser-563 plays a minor role in direct
activation of HSL. It also showed that the phosphorylation state of Ser-
660 is presumably more important in adipocytes at maximal lipolysis
[34]. All three PKA sites of HSL are phosphorylated both in vivo in
response to stimulation of rat adipocytes by isopreterenol and in vitro
upon incubation with PKA. In the present study, 0.1 μM berberine
completely abolished isopreterenol-stimulated HSL phosphorylation at
Ser-563, not at Ser-660. At this concentration, berberine did not reduce
Fig. 7. Berberine inhibited ERK1/2 phosphorylation, not perilipin phosphorylation. 3T3-
L1 adipocytes were incubated with 10 μM berberine (BBR) and 50 μM PD98059 for 1 h,
and then stimulated with 1 μM isoproterenol (ISO) and 10 μM forskolin (FKL) for
another 1 h. Equal amounts of cell lysates were analyzed by Western blot for the
phosphorylation of perilipin and ERK1/2. The image of immunodetected perilipin with
the characteristic phosphorylation-dependent molecular weight shift is representative
for at least three experiments.
534 L. Zhou et al. / Biochimica et Biophysica Acta 1812 (2011) 527–535isopreterenol-stimulated lipolysis signiﬁcantly. Thus, Ser-660 dephos-
phorylation is more related to the antilipolytic effect of berberine. At the
concentration of 10 μM, berberine dramatically decreased HSL phos-
phorylation at both Ser-563 and Ser-660 induced by isopreterenol,
noradrenaline, forskolin, IBMX, and cAMP, in good agreement with the
results of lipolysis, suggesting that the two phosphorylation sites can
account for the antilipolytic effect of berberine to a large extent.
In addition to the three PKA sites, one additional phosphorylation site
in HSL, Ser-565, has been shown to be phosphorylated in vitro as well as
in isolated primary adipocytes [8]. It has been shown in vitro that prior
phosphorylation of HSL by AMPK, which is the kinase proposed to be
responsible for phosphorylation of this site, prevents subsequent
phosphorylationbyPKAandviceversa.WhenAMPKactivity is increased
by AICAR, phenformin, or by the expression of a constitutively active
form, isoproterenol-induced lipolysis is strongly reduced [24]. Based on
the mutual exclusion between phosphorylation of Ser-565 and the PKA
sites, phosphorylation of the AMPK site has been proposed to play an
antilipolytic role [8]. As shown in Fig. 6A, AMPK activity was already
increased after 3T3-L1 adipocytes were incubated with berberine for
15 min and stayed at high level until 24 h (data not shown). However,
compoundC, anAMPK inhibitor, didnot reverse theantilipolytic effect of
berberine, nor the phosphorylations of ACC and AMPK stimulated by
berberine. As expected, berberine stimulated HSL Ser-565 phosphory-
lation. Whereas, compound C did not reverse berberine-inhibited HSL
phosphorylation at Ser-660, Ser-563, and Ser-565. Previously, we found
that compound C completely reversed troglitazone-suppressed glucose-
stimulated insulin secretion (GSIS), not berberine-suppressed GSIS [16].
Itwaspreviously reported that activation ofAMPKbyBBRdidnot rely on
theactivity of either LKB1or Ca2+/calmodulin-dependentprotein kinase
kinase (CAMKKβ) [14]. To further determine the role of AMPK in the
antilipolytic effect of berberine, AMPKα was knocked down, but
berberine-suppressed lipolysis was not reversed. These results suggest
that activation of AMPK is not involved in berberine-inhibited lipolysis.
It has recently been demonstrated that AMPK is activated by cAMP-
raising agents as a consequence of lipolysis in the adipocyte [35,36]. In
our previous study, fatty acids themselves can lead to an increased
activation of AMPK in isolated rat islets and MIN 6 beta cells [37]. In the
present study, forskolin and IBMX activated AMPK, but the two cAMP-
raising agents and berberine had no synergic effect on AMPK activity,
which may be due to the antilipolytic effect of berberine.
Perilipins belong to a family of hydrophobic lipid droplet-associated
phosphoproteins that are phosphorylated by PKA in multiple residues.
The function of perilipins is to prevent lipolysis in basal conditions,
favoring the lipid deposition. When HSL translocates to lipidic dropsurface, perilipins, which act as a barrier to enzyme action, are
phosphorylatedbyPKAand lose their blocking capability [38]. Berberine
completely reversedHSL Ser-563 and Ser-660 phosphorylation induced
by isoproterenol, but without effect on perilipin phosphorylation. This
may be why berberine partially decreased isoproterenol-stimulated
lipolysis, not completely. Additionally, we found that berberine
inhibited isoproterenol and forskolin-stimulated ERK1/2 phosphoryla-
tion. Previous studies have shown that cAMP can activate mitogen-
activated protein kinase (MAPK) pathways [39,40]. Furthermore, we
found that 8-bromo-cAMP and IBMX-induced ERK1/2 phosphorylation
was also decreased by berberine (data not shown). Therefore,
berberine-suppressed ERK1/2 phosphorylation stimulated by these
agents may be attributed to the decrease of the intracellular cAMP.
In conclusion, berberine attenuates catecholamines-stimulated
lipolysis in vitro, which is attributable to the decrease of PDE inhibition,
reduction of cAMP production, and inhibition of HSL activation. In our
previous study, berberine decreased plasma FFA in insulin-resistant rats
[16]. Whether berberine decreased lipolysis in vivo by these mechan-
isms need to be further investigated.Acknowledgments
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